One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS …
Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »
One of the questions I get asked most often is whether induced pluripotent stem cells (iPS cells) are well on their way to replacing ES (embryonic stem) cells. My answer? No. Not yet. iPS cells are great, but the original notion pushed by some that iPS cells would somehow replace ES cells, which would be …
Primary challenges facing iPS cells in late 2012 Read More »
Now six years into its existence, the induced pluripotent stem (iPS) cell field is no longer in its infancy to put it mildly but what will it take to get IPS cells to patients? Perhaps one might say that cutting edge new scientific fields advance in dog years. In that way of thinking, the iPS …
What does the FDA define as “minimally manipulated” when it comes to biologics such as stem cells? You will be shocked to find out, but they include irradiation and treatment with the super toxin/carcinogen, ethylene oxide. In a recent post I discussed the issue of an apparent “minimal manipulation” exception (some might even call it a …